{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-136715","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.474066+00:00","generated_at":"2026-06-02T02:24:54.432727+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verrica Q1 2024: YCANTH revenue $3.2M, net loss $20.3M, cash runway into Q1 2025","bullets":["YCANTH product revenue of $3.2M; no prior-year comparable as sales began Q3 2023.","Net loss $20.3M ($0.44/sh) vs $6.6M loss ($0.15/sh) in Q1 2023; non-GAAP loss $17.8M.","SG&A expense surged to $16.3M from $4.3M due to commercial ramp; R&D $4.9M vs $2.7M.","Cash and equivalents $48.9M; company expects to fund operations into Q1 2025.","Received NCE status (5-year exclusivity) and permanent J-Code for YCANTH; Phase 2 data for VP-315 (BCC) expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-136715","json":"https://secwatch.observer/filing/0001193125-24-136715.json","markdown":"https://secwatch.observer/filing/0001193125-24-136715.md","text":"https://secwatch.observer/filing/0001193125-24-136715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524136715/0001193125-24-136715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524136715/d805970d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:24:54.432727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f987374e0c8de86fad53614303546215d5497d34","claim":"Verrica Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $3.2 million.","evidence_excerpt":"Verrica recognized product revenue of $3.2 million in the first quarter of 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524136715/0001193125-24-136715-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}